

# China Renji



## Progress made on key issues

### Key points:

- Early solution to annual amortization charges
- Contract extensions from eight to 20 years with CD&T centres at 411 Hospital and 455 Hospital improving earnings stability and visibility
- One major acquisition to be announced by end-2008
- BUY call unchanged, HK\$0.20 target price maintained. Counter trading at a steep discount to other healthcare-related plays.

**Solution to the amortization issue.** China Renji (Renji) announced on 19 August that it had replaced its auditor Deloitte with SLP Horwath. In our view this means that the company has made progress in solving its amortization issue, which involves booking about HK\$54.0m a year in amortization costs related to the intangible asset of HK\$359.4m arising from lease and consultancy contracts from the acquisition of Anping Medical in Jul 2007.

**Working with partner hospitals and auditors.** In April, Renji said it would work with its partner hospitals and auditors to minimize the impact of the amortisation on its P&L. We understand that the new auditor has agreed to lower annual amortization charges after the company extended the contracts with 411 Hospital, 455 Hospital and Pudong Renji Hospital from an average of eight years to 20 years.

**Positive Surprise.** The announcement was a positive surprise as we previously expected the issue to be resolved by year-end at the earliest. The contract extension also improves Renji's earnings stability and visibility. The CD&T centres at 411 and 455 Hospitals in Shanghai are its core cash cows. We estimate that the two together generated 67.6% of its medical revenue in FY12/07A.

**M&As.** Since Apr 2008 (announcement of annual results), Renji has added five medical centres, in Xian, Shijiazhuang, Wuhan, Shenzhen and Shandong (Jinin), though these acquisitions are generally small in scale. However, we expect the company announce a large-scale acquisition before end-2008.

**Revising up our estimates.** We have left our revenue estimates unchanged but revised up Renji's net profit estimates by 27.9% to HK\$43.5m for FY12/08F and 17.0% to HK\$117.9m for FY12/09F. The revision is based on reduced amortization costs of HK\$20.0m, partially offset by slight increases in non-cash derivative finance costs, stock option expenses and unallocated corporate overheads, which we have previously underestimated in our model.

**1H FY12/08F preview.** The company is due to announce its 1H FY12/08F results on either 19th or 22nd Sep. We expect the bottom line to come in at HK\$11.8m. Note that Renji's results are heavily weighed towards 2H due to the combination of seasonally slower 1H (~45.0% of overall revenues). Many items, such as amortization, depreciation, finance costs, miscellaneous corporate expenses etc are booked 50.0% in 1H and 50.0% in 2H.

**BUY (unchanged)**

### China Healthcare

Wed, 03 Sep 2008

**Kennedy Tsang**

(852) 2533 3713

kennedytsang@sbi2capital.com

### Stock data

<b>Price</b>	<b>HK\$0.056</b>
<b>Target price</b>	HK\$0.20 (+257%)
<b>12 mth range</b>	HK\$0.057-0.230
<b>Market cap.</b>	US\$96.6m
<b>Daily t/o, 3 mth</b>	US\$0.41m
<b>Free float %</b>	70.5%
<b>Ticker</b>	0648.HK/648 HK

### Financial summary


Year to Dec	06A	07A	08F	09F	10F
Turnover (HK\$m)	9.1	58.5	189.1	273.0	312.6
Net Profit (HK\$m)	(83.0)	12.8	43.5	117.9	153.6
EPS (HK\$)	(0.018)	0.002	0.004	0.010	0.013
EPS Δ %	19.3	n/a	87.3	196.8	31.9
P/E (x)	n/a	35.2	14.7	5.4	4.2
P/B (x)	2.94	0.51	0.60	0.54	0.48
EV/EBITDA (x)	32.8	38.4	4.8	2.8	1.9
Yield (%)	-	-	-	-	-
ROE (%)	n/a	1.7	3.8	10.5	12.2
ROCE (%)	n/a	n/a	7.1	12.2	14.0
N. Gear. (%)	Cash	2.8	0.8	Cash	Cash

### Price Performance

	1 mth	3 mth	12 mth
Relative to HSI (%)	(17.8)	(32.6)	(68.7)
Actual price changes (%)	(25.7)	(42.9)	(72.9)

	08F	09F	10F
Consensus EPS (HK\$)	0.003	0.009	0.012
Previous forecasts (HK\$m)	34.0	100.8	133.0
Previous EPS (HK\$)	0.003	0.0090	0.0123

### Price Chart



**BUY unchanged, maintain target price.** At only 2.8x EV/EBITDA and 5.4x P/E based on FY12/09F numbers, the counter is trading at a deep discount to peers. Healthcare plays in Singapore are trading at an average of 10.2x EV/EBITDA despite operating in a more mature and smaller addressable market, while Apollo Hospitals (APHS IN) in India is trading at a one-year forward EV/EBITDA of 11.1x. Our target price remains HK\$0.20, representing 10.0x FY12/09F EV/EBITDA and 20.0x FY12/09F P/E.

**Table 1: P&L**

Year to Dec (HK\$m)	06A	07A	08F	09F	10F
<b>Revenues</b>	<b>9.1</b>	<b>58.5</b>	<b>189.1</b>	<b>273.0</b>	<b>312.6</b>
Cost of sales	(0.9)	(33.8)	(35.3)	(42.8)	(44.5)
<b>Gross profit</b>	<b>8.2</b>	<b>24.6</b>	<b>153.8</b>	<b>230.2</b>	<b>268.0</b>
Other revenues	5.9	5.0	5.6	6.1	6.7
Distribution expenses	-	-	-	-	-
Administrative expenses	(40.0)	(64.1)	(55.2)	(56.5)	(57.6)
Exceptionals	(16.3)	(13.5)	-	-	-
Finance costs	(3.9)	(26.6)	(24.2)	(14.0)	(8.1)
Share of results from associates	(54.6)	(0.7)	-	-	-
<b>Profit before tax</b>	<b>(100.8)</b>	<b>(75.4)</b>	<b>79.9</b>	<b>165.9</b>	<b>209.1</b>
Tax	-	(1.5)	(33.0)	(42.9)	(49.6)
<b>Profit from continuing operations</b>	<b>(100.8)</b>	<b>(77.0)</b>	<b>46.9</b>	<b>123.0</b>	<b>159.4</b>
Profit from discontinued operations	17.3	93.7	-	-	-
Profit for the year	(83.4)	16.8	46.9	123.0	159.4
Minority interest	0.4	(4.0)	(3.4)	(5.0)	(5.8)
<b>Net profit</b>	<b>(83.0)</b>	<b>12.8</b>	<b>43.5</b>	<b>117.9</b>	<b>153.6</b>

Source: Company data, SBI E2-Capital

SBI E2-Capital is a dedicated small/mid cap investment banking/ stockbrokerage house. Find our research on: [sbie2capital.com](http://sbie2capital.com), [thomsononeanalytics.com](http://thomsononeanalytics.com), [factset.com](http://factset.com) and [multex.com](http://multex.com)

**SBI E2-Capital stock ratings:**

**STRONG BUY** : absolute upside of >50% over the next three months

**BUY** : absolute upside of >10% over the next six months

**HOLD** : absolute return of -10% to +10% over the next six months

**SELL** : absolute downside of >10% over the next six months

Investors should assume that SBI E2-Capital is seeking or will seek investment banking or other related businesses with the companies in this report.

**Analyst certification:** The views expressed in this report accurately reflect the analyst's personal views of the subject securities and that the analyst has not received and will not receive direct or indirect compensation in exchange for expressing specific recommendations or views in this report.

**Disclaimer:** This research report is not an offer to sell or the solicitation of an offer to buy or subscribe for any securities. The securities referred to in this report may not be eligible for sale in some jurisdictions. The information contained in this report has been compiled by the Research Department of SBI E2-Capital Securities Limited ('SBI E2-Capital') from sources that it believes to be reliable but no representation, warranty or guarantee is made or given by SBI E2-Capital or any other person as to its accuracy or completeness. All opinions and estimates expressed in this report are (unless otherwise indicated) entirely those of SBI E2-Capital as of the date of this report only and are subject to change without notice. Neither SBI E2-Capital nor any other person, accepts any liability whatsoever for any loss howsoever arising from any use of this report or its contents or otherwise arising in connection therewith. Each recipient of this report shall be solely responsible for making its own independent investigation of the business, financial condition and prospects of the companies referred to in this report. SBI E2-Capital and their respective officers, directors and employees, including persons involved in the preparation or issuance of this report, may from time to time (1) have positions in, and buy or sell, the securities of companies referred to in this report (or related investments); (2) have a consulting, investment banking or broking relationship with any company referred to in this report; and (3) to the extent permitted under applicable law, have acted upon or used the information contained or referred to in this report including effecting transactions for their own account in an investment (or related investment) in respect of any company referred to in this report, prior to or immediately following its publication. This report may not have been distributed to all recipients at the same time. This report is issued only for the information of and may only be distributed to professional investors and dealers in securities and must not be copied, published, reproduced or redistributed (in whole or in part) by any recipient for any purpose. This report is distributed in Hong Kong by SBI E2-Capital. Any recipient of this report who requires further information regarding any securities referred to in this report should contact the relevant office of SBI E2-Capital located in such recipient's home jurisdiction.

Copyright © SBI E2-Capital Securities Limited 2008. All rights reserved.